Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Masayuki Sho

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6208-7661; OpenAlex author ID A5035027513, A5113062203. Sources: OpenAlex.

Their work

Papers
88 (first author 18, last author 21)
Trials
0
Grants
0
Labs led
1
Collaborators
233
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 4 papers · 2014: 2 papers · 2015: 12 papers · 2016: 8 papers · 2017: 3 papers · 2018: 4 papers · 2019: 9 papers · 2020: 2 papers · 2021: 6 papers · 2022: 4 papers · 2023: 12 papers · 2024: 6 papers · 2025: 5 papers · 2026: 6 papers

Papers 50 of 88

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  3. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  4. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… Last author DOI 10.1097/sla.0000000000007012↗
  5. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  6. Adaptive Surgical Decision-Making for Synchronous Metastatic Pancreatic Cancer and Early Breast Cancer with a BRCA1 Pathogenic Variant: A Case Report. Last author DOI 10.70352/scrj.cr.26-0257↗
  7. Role of radiotherapy in surgical approaches to pancreatic cancer treatment: A narrative review. Last author DOI 10.1002/ags3.70012↗
  8. Efficacy and Safety of Surgical Treatment Among Older Adult Patients (80 Years) With Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1002/jhbp.12151↗
  9. An axon guidance-related microRNA panel identifies perivascular plexus local recurrence following curative surgery in patients with pancreatic cancer. Last author DOI 10.1007/s00535-025-02260-w↗
  10. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  11. Endoscopic biliary drainage with multi-hole self-expandable metallic stent during neoadjuvant chemoradiotherapy in pancreatic cancer. Last author DOI 10.4253/wjge.v17.i11.111107↗
  12. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement. Last author DOI 10.1002/ags3.12726↗
  13. Prognostic significance of creatine kinase in resected pancreatic cancer. Last author DOI 10.1002/jhbp.12081↗
  14. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites. Last author DOI 10.1016/j.pan.2024.07.013↗
  15. Clinical impact of carbonic anhydrase 9 expression on neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2024.08.003↗
  16. Clinical significance and therapeutic implication of CD200 in pancreatic cancer. Last author DOI 10.1016/j.pan.2024.10.007↗
  17. Critical Role of Preoperative Hyperglycemia in Association with GFAT-1 Expression in Resected Pancreatic Cancer. Last author DOI 10.1245/s10434-024-15985-4↗
  18. Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12629↗
  19. Essential updates 2021/2022: Surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12655↗
  20. Gastrojejunostomy versus endoscopic duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer: a propensity score… Co-author DOI 10.1007/s00464-022-09685-x↗
  21. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  22. Significance of multiple tumor markers measurements in conversion surgery for unresectable locally advanced pancreatic cancer. Last author DOI 10.1016/j.pan.2023.06.001↗
  23. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  24. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  25. Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic du… Last author DOI 10.1016/j.pan.2023.10.014↗
  26. Clinical significance and functional role of adhesion G-protein-coupled receptors in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-022-02057-1↗
  27. Identification of Nectin Family Interactive Gene Panel and Stratification of Clinical Outcomes in Patients with Pancreatic Cancer. Last author DOI 10.1097/xcs.0000000000000808↗
  28. Pancreatic ductal adenocarcinoma arising from the pancreatic parenchyma compressed by a huge pancreatic lipoma: a case report. Last author DOI 10.1186/s40792-023-01720-w↗
  29. Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms24087506↗
  30. Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis. Co-author DOI 10.1002/jhbp.1127↗
  31. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer. Last author DOI 10.1007/s10147-022-02131-x↗
  32. Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models. Last author DOI 10.1038/s41598-022-26863-y↗
  33. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  34. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. First author DOI 10.1002/ijc.33284↗
  35. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2020.12.031↗
  36. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. First author DOI 10.1016/j.pan.2021.01.013↗
  37. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Last author DOI 10.1016/j.pan.2021.03.008↗
  38. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic … Co-author DOI 10.1097/sla.0000000000003487↗
  39. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.3390/jcm10040873↗
  40. Application of liquid biopsy for surgical management of pancreatic cancer. First author DOI 10.1002/ags3.12317↗
  41. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. First author DOI 10.1053/j.gastro.2020.04.057↗
  42. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. First author DOI 10.1007/s00268-018-4791-7↗
  43. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  44. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… First author DOI 10.1007/s00268-018-4820-6↗
  45. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. Co-author DOI 10.1007/s00535-018-1506-7↗
  46. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. First author DOI 10.1016/j.pan.2019.05.461↗
  47. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Co-author DOI 10.1093/jjco/hyy190↗
  48. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  49. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializi… Co-author DOI 10.1245/s10434-018-07131-8↗
  50. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. First author DOI 10.1634/theoncologist.2018-0900↗

Closest collaborators

The 25 strongest of 233 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minako Nagai · 44 shared papers, 2015–2026 · strength 5.69
  2. Kota Nakamura · 24 shared papers, 2018–2025 · strength 3.87
  3. Satoshi Yasuda · 22 shared papers, 2012–2026 · strength 3.54
  4. Taichi Terai · 19 shared papers, 2021–2025 · strength 3.44
  5. Sohei Satoi · 34 shared papers, 2013–2026 · strength 3.15
  6. Satoshi Nishiwada · 28 shared papers, 2015–2025 · strength 2.80
  7. Takahiro Akahori · 33 shared papers, 2011–2026 · strength 2.74
  8. Yuichiro Kohara · 13 shared papers, 2023–2025 · strength 2.60
  9. Michiaki Unno · 21 shared papers, 2014–2026 · strength 2.00
  10. Hiroki Yamaue · 23 shared papers, 2013–2026 · strength 1.89
  11. Ippei Matsumoto · 21 shared papers, 2014–2026 · strength 1.76
  12. Yoshiaki Murakami · 19 shared papers, 2014–2026 · strength 1.51
  13. Kenji Nakagawa · 12 shared papers, 2018–2023 · strength 1.39
  14. Tsutomu Fujii · 9 shared papers, 2018–2026 · strength 1.25
  15. Goro Honda · 16 shared papers, 2014–2026 · strength 1.24
  16. Kenichiro Uemura · 14 shared papers, 2015–2026 · strength 1.21
  17. Fuyuhiko Motoi · 15 shared papers, 2014–2026 · strength 1.04
  18. Satoshi Hirano · 6 shared papers, 2013–2026 · strength 0.99
  19. Yoshiyuki Nakajima · 23 shared papers, 2011–2016 · strength 0.97
  20. Shoichi Kinoshita · 17 shared papers, 2012–2024 · strength 0.94
  21. Tadataka Takagi · 7 shared papers, 2019–2023 · strength 0.93
  22. Toshihiro Tanaka · 13 shared papers, 2011–2025 · strength 0.88
  23. Hiroaki Yanagimoto · 17 shared papers, 2013–2019 · strength 0.87
  24. Suguru Yamada · 6 shared papers, 2017–2026 · strength 0.86
  25. Naoya Ikeda · 10 shared papers, 2015–2021 · strength 0.81

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.